Pacira BioSciences (PCRX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Pacira BioSciences (PCRX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.59% |
| Mar 31, 2026 | -22.34% |
| Dec 31, 2025 | -35.38% |
| Sep 30, 2025 | 58.01% |
| Jun 30, 2025 | -27.87% |
| Mar 31, 2025 | 5.35% |
| Dec 31, 2024 | 39.42% |
| Sep 30, 2024 | -79.88% |
| Jun 30, 2024 | 49.81% |
| Mar 31, 2024 | 55.97% |
| Dec 31, 2023 | 242.49% |
| Sep 30, 2023 | 60.42% |
| Jun 30, 2023 | 176.30% |
| Mar 31, 2023 | -193.30% |
| Dec 31, 2022 | -145.19% |
| Sep 30, 2022 | -21.66% |
| Jun 30, 2022 | 43.36% |
| Mar 31, 2021 | 36.15% |
| Dec 31, 2020 | 50.87% |
| Sep 30, 2020 | -17.34% |